Global Directory of Pharmaceutical, Biotech and Diagnostic Asset Purchase Partnerships 2014-2021: Focus on Commercial Assets, Product Assets, Royalty Assets and Technology Assets | News

0

DUBLIN, March 22, 2022 /PRNewswire/ — The report “Global Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014 to 2021” has been added to from ResearchAndMarkets.com offer.

The Global Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2014-2020 report provides full access to available records for over 1,200 asset purchase deals, including contract documents when available.

The report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets.

The report focuses on partnerships for business, product, technology and royalty assets where the partners have entered into an agreement to transfer or acquire said assets.

Businesses may seek to dispose of an asset simply because it is surplus to requirements. Or it may seek to divest assets in order to raise funds to invest in other parts of its business. Or it may be due to a regulatory obligation to divest certain business assets or products as a result of a pending corporate merger in order to comply with competition regulations.

The report provides access to the payment terms of the asset purchase agreements as announced between the parties. This data provides useful information about the payment and other terms of the transaction.

The report focuses on four main types of assets available for purchase:

Trading assets – the most common asset trading hands. Business assets are in the form of a business unit or a subsidiary of a parent company. Common assets include territorial businesses or non-core businesses such as an OTC or diagnostics business, separate from core business activities

Product Assets – in the form of a marketed product, clinical-stage development compound, or drug-compound combination. These assets are generally available following a merger or a change in management of the selling company. The buyer acquires the property for global or territorial use. Often the acquirer is normally a competitor of the seller, but in this situation the trade is mutually beneficial

Royalty assets – where a specialist investment company acquires the rights to future royalty payments in return for paying a lump sum payment to the licensor for the proceeds

Technology Asset – when a buyer acquires a technology platform, research program, patent portfolio, or other intellectual property asset. The acquisition is often due to the technology being surplus to the interests of the seller, but can also result from a sale of assets before the seller enters liquidation

The report includes deals announced by hundreds of life science companies, including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva and Valeant, among many others.

Key Benefits

  • Global Asset Purchase Deals in the Pharmaceutical, Biotech and Diagnostics Sectors 2014-2021 provide the reader with the following key benefits:
  • In-depth understanding of asset purchase trade trends since 2014
  • Analysis of the structure of asset purchase contracts with many real case studies
  • Full access to over 1,200 real asset purchase deals made by the world’s biopharmaceutical companies
  • Detailed access to real asset purchase deals made by major biopharmaceutical companies
  • Overview of the terms included in an asset purchase agreement, along with examples of real-world clauses
  • Understand the key terms of agreement that companies have agreed to in previous agreements
  • Undertake due diligence to assess the suitability of the terms of the agreement you propose for business partners

In Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2014-2021, available deals are listed by:

  • A-Z company
  • Face value
  • Stage of development at signing
  • Therapeutic space
  • Type of technology

The analysis of the actual contractual agreements makes it possible to evaluate the following elements:

  • What specific rights are granted or optional?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the transaction?
  • How are sales and payments audited?
  • What is the duration of the agreement?
  • How are the main terms of the agreement defined?
  • How are IPRs managed and owned?
  • Who is responsible for marketing?
  • Who is responsible for development, supply and manufacturing?
  • How are confidentiality and publication managed?
  • How to settle disputes?
  • Under what conditions can the agreement be terminated?
  • What happens if the owner changes?
  • What sub-licensing and sub-contracting arrangements have been agreed upon?
  • What boilerplate clauses does the company insist on?
  • What boilerplate clauses seem to differ from one partner to another or from one type of transaction to another?
  • What jurisdiction does the company insist on for contract law?

Main topics covered:

Abstract

Chapter 1 Introduction

Chapter 2 – Trends in asset purchase transactions

2.1. introduction

2.2. Types of assets purchased

2.3. Trends in asset purchase transactions since 2014

2.3.1. Asset purchase transactions by year since 2014

2.3.2. Asset purchase transactions by development phase since 2014

2.3.3. Asset purchase transactions by industry sector since 2014

2.3.4. Asset purchase transactions by therapeutic area since 2014

2.3.5. Asset purchase transactions by type of technology since 2014

2.3.6. Asset purchase transactions by most active company since 2014

2.4. Reasons for Entering into Asset Purchase Partnership Agreements

2.4.1. Business assets

2.4.2. Product Assets

2.4.3. Royalty assets

2.4.4. Technology assets

2.5 The emergence of royalty asset purchase agreements

2.5.1. Principal Players in Royalty Asset Purchase Agreements

2.5.3. The Future of Royalty Asset Purchase Agreements

2.6. The role of intellectual property auction houses in asset purchase transactions

2.6.1. Top IP Auction Companies

2.7. The future of asset purchase agreements

Chapter 3 – Presentation of the structure of the asset purchase transaction

3.1. introduction

3.2. Structure of the Asset Purchase Agreement

3.3. Examples of Asset Purchase Agreements

3.3.1. Case Study 1: Product Advantage: QLT – Valeant Pharmaceuticals

3.3.2. Case Study 2: Business Asset: Merck and Co – Bayer

3.4. Anatomy of a Royalty Asset Purchase Agreement

3.5. Examples of Royalty Asset Purchase Agreements

3.5.1. Case Study 3: Royalty Asset: BioTime Acquisition Corporation – Geron Corporation

Chapter 4 – Main Asset Purchase Agreements

4.1. introduction

4.2. Top asset purchase transactions by value

Chapter 5 – Top 25 Most Active Asset Buy Traders

5.1. introduction

5.2. Top 25 Most Active Asset Buy Traders

Chapter 6 – Offers to purchase assets, including contract directory

6.1. introduction

6.2. Asset purchase deals contracts since 2014

For more information about this report visit https://www.researchandmarkets.com/r/mpm65p

Media Contact:

Research and Markets

Laura Woodsenior

press@researchandmarkets.com

For EST office hours, call +1-917-300-0470

For USA/CAN call toll free +1-800-526-8630

For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907

Fax (outside the US): +353-1-481-1716

View original content: https://www.prnewswire.com/news-releases/global-pharma-biotech-and-diagnostics-asset-purchase-partnering-directory-2014-2021-focus-on-business-assets-product -assets-royalty-assets–technology-assets-301507597.html

SOURCE Research and Markets

Share.

Comments are closed.